Disease Detail

ID DOID:1612
Name breast cancer
Definition A thoracic cancer that originates in the mammary gland.
Source DiseaseOntology.org
Alt Ids DOID:4241 DOID:1648
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 P72R Daunorubicin breast cancer predicted - sensitive detail...
TP53 P72R Daunoxome breast cancer predicted - sensitive detail...
TP53 P72R Doxil breast cancer predicted - sensitive detail...
TP53 P72R epirubicin breast cancer sensitive detail...
ERBB2 amp Temsirolimus + Neratinib breast cancer predicted - sensitive detail...
Unknown unknown PD-0325901 breast cancer not applicable detail...
TP53 P72R TP53 Y220C Epirubicin + Cyclophosphamide breast cancer no benefit detail...
ATM dec exp Talazoparib breast cancer sensitive detail...
ERBB2 amp Dacomitinib breast cancer sensitive detail...
TP53 inact mut MK-1775 + Radiotherapy breast cancer sensitive detail...
ERBB2 amp ERBB2 T798M Trastuzumab breast cancer resistant detail...
ERBB2 T798M Buparlisib breast cancer sensitive detail...
ERBB2 T798M XL147 breast cancer sensitive detail...
ERBB2 T798M Afatinib breast cancer sensitive detail...
ERBB2 T798M Cetuximab breast cancer resistant detail...
ERBB2 T798M Cetuximab + Lapatinib breast cancer sensitive detail...
ERBB2 T798M Trastuzumab + Lapatinib breast cancer sensitive detail...
ERBB2 T798M Trastuzumab + XL147 breast cancer sensitive detail...
ERBB2 T798M CI-1040 breast cancer resistant detail...
TP53 negative Avastin + Doxorubicin + Docetaxel breast cancer sensitive detail...
Unknown unknown Vandetanib + Cyclophosphamide + Methotrexate breast cancer not applicable detail...
Unknown unknown Cabozantinib breast cancer not applicable detail...
Unknown unknown Axitinib breast cancer not applicable detail...
Unknown unknown Pazopanib breast cancer not applicable detail...
TP53 inact mut AMG 900 breast cancer sensitive detail...
BRCA1 mutant Olaparib breast cancer sensitive detail...
BRCA1 V340* Olaparib breast cancer sensitive detail...
BRCA2 inact mut Olaparib breast cancer sensitive detail...
BRCA2 mutant Olaparib breast cancer sensitive detail...
BRCA1 loss Carboplatin breast cancer sensitive detail...
BRAF G464V KRAS G13D Regorafenib breast cancer sensitive detail...
Unknown unknown GDC-0349 breast cancer not applicable detail...
ERBB2 over exp AV-412 breast cancer sensitive detail...
FGFR2 amp Dovitinib breast cancer sensitive detail...
BRCA1 C61G TP53 loss Olaparib breast cancer decreased response detail...
ERBB2 D769H Lapatinib breast cancer sensitive detail...
ERBB2 D769H Neratinib breast cancer sensitive detail...
ERBB2 D769H Trastuzumab breast cancer sensitive detail...
ERBB2 D769Y Lapatinib breast cancer sensitive detail...
ERBB2 D769Y Neratinib breast cancer sensitive detail...
ERBB2 D769Y Trastuzumab breast cancer sensitive detail...
ERBB2 G309A Lapatinib breast cancer sensitive detail...
ERBB2 G309A Neratinib breast cancer sensitive detail...
ERBB2 G309A Trastuzumab breast cancer sensitive detail...
ERBB2 L755S Neratinib breast cancer sensitive detail...
ERBB2 G778_P780dup Lapatinib breast cancer resistant detail...
ERBB2 G778_P780dup Neratinib breast cancer sensitive detail...
ERBB2 G778_P780dup Trastuzumab breast cancer resistant detail...
ERBB2 R678Q Lapatinib breast cancer sensitive detail...
ERBB2 R678Q Neratinib breast cancer sensitive detail...
ERBB2 R896C Lapatinib breast cancer sensitive detail...
ERBB2 R896C Neratinib breast cancer sensitive detail...
ERBB2 R896C Trastuzumab breast cancer sensitive detail...
ERBB2 V777L Lapatinib breast cancer sensitive detail...
ERBB2 V777L Neratinib breast cancer sensitive detail...
ERBB2 V777L Trastuzumab breast cancer sensitive detail...
ERBB2 V842I Lapatinib breast cancer sensitive detail...
ERBB2 V842I Neratinib breast cancer sensitive detail...
ERBB2 V842I Trastuzumab breast cancer sensitive detail...
FBXW7 inact mut Sirolimus breast cancer sensitive detail...
PTEN mutant Sapanisertib breast cancer sensitive detail...
Unknown unknown A-1331852 + Docetaxel breast cancer not applicable detail...
Unknown unknown Fluoxymesterone breast cancer not applicable detail...
Unknown unknown Verrucarin A + Tamoxifen breast cancer not applicable detail...
Unknown unknown ON01910 + Aldoxorubicin breast cancer not applicable detail...
ETV6-NTRK3 BMS-754807 breast cancer sensitive detail...
ARID1A dec exp Talazoparib breast cancer conflicting detail...
FGFR2 over exp AZ8010 breast cancer sensitive detail...
FGFR2 over exp AZD4547 breast cancer sensitive detail...
ERBB2 amp CH5132799 breast cancer sensitive detail...
BRAF G464V KRAS G13D CH5132799 breast cancer decreased response detail...
PTEN A72fs Gedatolisib breast cancer sensitive detail...
BRAF G464V KRAS G13D Gedatolisib breast cancer sensitive detail...
FGFR2 over exp PD173074 breast cancer sensitive detail...
Unknown unknown CWP232228 breast cancer not applicable detail...
Unknown unknown Tanibirumab breast cancer not applicable detail...
FGFR1 amp Ponatinib breast cancer sensitive detail...
FGFR2 amp Ponatinib breast cancer sensitive detail...
FGFR2 wild-type Ponatinib breast cancer resistant detail...
FGFR1 wild-type Ponatinib breast cancer resistant detail...
ERBB2 over exp KU004 breast cancer sensitive detail...
Unknown unknown Gemcitabine + GSK1120212 breast cancer not applicable detail...
Unknown unknown Selumetinib breast cancer not applicable detail...
AKT1 E17K Capivasertib breast cancer sensitive detail...
Unknown unknown Eribulin breast cancer not applicable detail...
Unknown unknown KW-2450 breast cancer not applicable detail...
FGFR1 act mut FIIN-01 breast cancer sensitive detail...
AKT1 W80A MK2206 breast cancer resistant detail...
FGFR2 amp FF-284 breast cancer sensitive detail...
Unknown unknown NTRC 0066-0 breast cancer not applicable detail...
ARID1A dec exp Olaparib breast cancer sensitive detail...
ARID1A dec exp Veliparib breast cancer sensitive detail...
ARID1A dec exp Rucaparib breast cancer sensitive detail...
Unknown unknown MEDI5117 + Docetaxel breast cancer not applicable detail...
Unknown unknown COG112 breast cancer not applicable detail...
ERBB2 positive Withacnistin breast cancer sensitive detail...
PTEN loss AZD6482 breast cancer sensitive detail...
PTEN loss GSK2636771 breast cancer sensitive detail...
TP53 L194F Tanespimycin + Vorinostat breast cancer sensitive detail...
TP53 L194F Tanespimycin breast cancer sensitive detail...
TP53 L194F Vorinostat breast cancer sensitive detail...
TP53 R280K Ganetespib breast cancer sensitive detail...
TP53 L194F Ganetespib breast cancer sensitive detail...
TP53 R175H Ganetespib breast cancer sensitive detail...
CDH1 R63* ERBB2 L869Q Lapatinib + Capecitabine breast cancer sensitive detail...
Unknown unknown F14512 breast cancer not applicable detail...
Unknown unknown TAK-960 breast cancer not applicable detail...
Unknown unknown AIM-100 breast cancer not applicable detail...
ALK wild-type Dalantercept + Cisplatin breast cancer predicted - sensitive detail...
ERBB2 act mut STK11 loss AZD8055 breast cancer sensitive detail...
RET positive Y078-DM4 breast cancer sensitive detail...
RET over exp Y078-DM1 breast cancer sensitive detail...
Unknown unknown GSK2126458 breast cancer not applicable detail...
Unknown unknown ST7612AA1 breast cancer not applicable detail...
Unknown unknown AZD7762 + VE-821 breast cancer not applicable detail...
MET over exp Crizotinib + Rucaparib breast cancer sensitive detail...
Unknown unknown AKI603 breast cancer not applicable detail...
Unknown unknown AKI603 + Epirubicin breast cancer not applicable detail...
Unknown unknown AB61 breast cancer not applicable detail...
Unknown unknown EHop-016 breast cancer not applicable detail...
Unknown unknown Thymoquinone breast cancer not applicable detail...
CBLC dec exp Olaparib breast cancer predicted - sensitive detail...
RAD21 wild-type N/A breast cancer not applicable detail...
Unknown unknown Carboplatin + E7449 breast cancer not applicable detail...
Unknown unknown Paclitaxel + TVB-2640 breast cancer not applicable detail...
Unknown unknown Gedatolisib breast cancer not applicable detail...
Unknown unknown Veliparib + Carboplatin breast cancer not applicable detail...
BRCA1 mutant Veliparib + Carboplatin breast cancer predicted - sensitive detail...
BRCA2 mutant Veliparib + Carboplatin breast cancer predicted - sensitive detail...
BRCA1 mutant Niraparib breast cancer predicted - sensitive detail...
BRCA1 mutant Talazoparib breast cancer predicted - sensitive detail...
ERBB2 L755_T759del Lapatinib breast cancer resistant detail...
ERBB2 L755_T759del Gefitinib breast cancer sensitive detail...
ERBB2 L755_T759del Neratinib breast cancer sensitive detail...
ERBB2 amp Afatinib breast cancer sensitive detail...
ERBB2 L726F Lapatinib breast cancer resistant detail...
ERBB2 act mut Neratinib breast cancer sensitive detail...
NOTCH1 positive LY3039478 breast cancer sensitive detail...
NOTCH1 act mut Brontictuzumab breast cancer sensitive detail...
Unknown unknown Vantictumab + Paclitaxel breast cancer not applicable detail...
ERBB2 L726I Gefitinib breast cancer resistant detail...
Unknown unknown Pemetrexed + Sorafenib breast cancer not applicable detail...
Unknown unknown CPI-455 + Lapatinib breast cancer sensitive detail...
BRCA1 mutant Denosumab breast cancer not applicable detail...
Unknown unknown RapaLink-1 breast cancer not applicable detail...
Unknown unknown Irinotecan + Veliparib breast cancer not applicable detail...
FGFR1 amp AZD4547 breast cancer no benefit detail...
Unknown unknown AZD8186 breast cancer not applicable detail...
Unknown unknown MLN1117 breast cancer not applicable detail...
Unknown unknown Pyr1 breast cancer not applicable detail...
ERBB2 amp Lapatinib breast cancer decreased response detail...
ERBB2 amp Torkinib breast cancer sensitive detail...
ERBB2 amp Lapatinib + Torkinib breast cancer sensitive detail...
Unknown unknown Alisertib breast cancer not applicable detail...
Unknown unknown Alisertib + Eribulin breast cancer not applicable detail...
Unknown unknown WANT3 breast cancer not applicable detail...
TP53 wild-type AMG 232 breast cancer sensitive detail...
TP53 wild-type AMG 232 + Radiotherapy breast cancer sensitive detail...
Unknown unknown GSK1904529A breast cancer not applicable detail...
FGFR2 amp FGFR2 fusion PRN1371 breast cancer sensitive detail...
PTEN mutant MS417 + Pictilisib breast cancer predicted - sensitive detail...
BRCA1 wild-type Olaparib breast cancer resistant detail...
BRCA1 loss Olaparib breast cancer sensitive detail...
BRCA1 L1795Pfs*3 Olaparib breast cancer sensitive detail...
BRCA1 E23Vfs*17 Olaparib breast cancer decreased response detail...
Unknown unknown OSI-027 breast cancer not applicable detail...
PTEN loss OSI-027 breast cancer sensitive detail...
ERBB2 L768S Trastuzumab breast cancer sensitive detail...
ERBB2 L768S Lapatinib breast cancer sensitive detail...
ERBB2 L768S Neratinib breast cancer sensitive detail...
ERBB2 V773L Trastuzumab breast cancer sensitive detail...
ERBB2 V773L Lapatinib breast cancer sensitive detail...
ERBB2 V773L Neratinib breast cancer sensitive detail...
ERBB2 K753E Trastuzumab breast cancer resistant detail...
ERBB2 K753E Lapatinib breast cancer resistant detail...
ERBB2 K753E Neratinib breast cancer sensitive detail...
AKT1 E17K BAY1125976 breast cancer sensitive detail...
PTEN L108R BAY1125976 breast cancer sensitive detail...
PTEN T319fs BAY1125976 breast cancer sensitive detail...
ERBB2 V659E 23814 + Tivozanib breast cancer sensitive detail...
ERBB2 positive DS-8201a breast cancer sensitive detail...
PTEN C136Y Alpelisib breast cancer resistant detail...
PTEN loss Alpelisib breast cancer resistant detail...
BRCA1 mutant AZD2461 breast cancer sensitive detail...
BRCA2 inact mut AZD2461 breast cancer sensitive detail...
BRCA1 loss TP53 loss AZD2461 breast cancer sensitive detail...
ERBB2 amp Lapatinib + S63845 breast cancer sensitive detail...
Unknown unknown PU-H71 breast cancer not applicable detail...
FGFR2 positive BAY1187982 breast cancer sensitive detail...
FGFR2 dec exp BAY1187982 breast cancer resistant detail...
FGFR2 amp AZD4547 breast cancer sensitive detail...
FGFR1 amp FGFR2 amp E7090 breast cancer sensitive detail...
Unknown unknown SL0101 breast cancer not applicable detail...
ARID1A loss AZD8055 + MK2206 breast cancer sensitive detail...
ARID1A loss ERBB2 amp MK2206 + Trastuzumab breast cancer sensitive detail...
Unknown unknown VS-5584 breast cancer not applicable detail...
TP53 wild-type SAR405838 breast cancer predicted - sensitive detail...
Unknown unknown Metformin breast cancer not applicable detail...
Unknown unknown Everolimus breast cancer not applicable detail...
Unknown unknown Everolimus + Metformin breast cancer not applicable detail...
Unknown unknown LDC1267 breast cancer not applicable detail...
FGFR1 amp BGJ398 breast cancer sensitive detail...
FGFR2 amp BGJ398 breast cancer sensitive detail...
PTEN mutant CUDC-907 breast cancer sensitive detail...
PTEN del CUDC-907 breast cancer sensitive detail...
Unknown unknown GTCpFE breast cancer not applicable detail...
Unknown unknown Afatinib + Vinorelbine breast cancer not applicable detail...
BRCA1 inact mut Carboplatin + Paclitaxel + Veliparib breast cancer predicted - sensitive detail...
BRCA2 inact mut Carboplatin + Paclitaxel + Veliparib breast cancer predicted - sensitive detail...
KDR over exp Sunitinib breast cancer predicted - resistant detail...
Unknown unknown Altiratinib breast cancer not applicable detail...
Unknown unknown NSC23766 breast cancer not applicable detail...
PTEN L108R DHM25 breast cancer sensitive detail...
PTEN loss Everolimus breast cancer resistant detail...
PTEN loss Torkinib breast cancer resistant detail...
Unknown unknown AJI-100 breast cancer not applicable detail...
Unknown unknown AJI-214 breast cancer not applicable detail...
ERBB2 L869R Lapatinib breast cancer resistant detail...
ERBB2 L869R Erlotinib breast cancer resistant detail...
Unknown unknown DCBCI0901 breast cancer not applicable detail...
TP53 R175H NSC319726 breast cancer sensitive detail...
TP53 R273W NSC319726 breast cancer resistant detail...
TP53 positive Serdemetan breast cancer sensitive detail...
Unknown unknown CVX-241 breast cancer not applicable detail...
BRCA1 mutant Pamiparib breast cancer sensitive detail...
Unknown unknown BGP-15 breast cancer not applicable detail...
Unknown unknown MBQ-167 breast cancer not applicable detail...
KRAS G13D 3144 breast cancer sensitive detail...
BRCA2 dec exp NU1025 breast cancer sensitive detail...
ERBB2 over exp MM-302 + Trastuzumab breast cancer sensitive detail...
ERBB2 positive ADCT-502 breast cancer sensitive detail...
Unknown unknown E7046 + Radiotherapy breast cancer not applicable detail...
Unknown unknown V158411 breast cancer not applicable detail...
ERBB2 positive XMT-1522 breast cancer sensitive detail...
TP53 mutant PK11007 breast cancer sensitive detail...
BRCA2 mutant Talazoparib breast cancer predicted - sensitive detail...
ERBB2 L869R Neratinib breast cancer sensitive detail...
ERBB2 L869R Afatinib breast cancer sensitive detail...
Unknown unknown Azacitidine + Entinostat breast cancer not applicable detail...
Unknown unknown ONC201 breast cancer not applicable detail...
ERBB2 amp Buparlisib breast cancer sensitive detail...
ERBB2 amp LJM716 + Trastuzumab breast cancer sensitive detail...
ERBB2 amp Pertuzumab + Trastuzumab breast cancer sensitive detail...
ERBB2 amp LJM716 + Neratinib breast cancer sensitive detail...
ERBB2 amp Neratinib + Pertuzumab breast cancer sensitive detail...
MET amp TP53 del Crizotinib breast cancer sensitive detail...
Unknown unknown Barasertib breast cancer not applicable detail...
Unknown unknown JNJ-7706621 breast cancer not applicable detail...
Unknown unknown Danusertib breast cancer not applicable detail...
Unknown unknown Danusertib + Fulvestrant breast cancer not applicable detail...
Unknown unknown Alisertib + Fulvestrant breast cancer not applicable detail...
Unknown unknown Fulvestrant + JNJ-7706621 breast cancer not applicable detail...
ERBB2 mutant Neratinib breast cancer predicted - sensitive detail...
ERBB2 S310F ERBB2 V842I Neratinib breast cancer predicted - sensitive detail...
Unknown unknown H3B-6545 breast cancer not applicable detail...
Unknown unknown Hydroxyurea + NU6027 breast cancer not applicable detail...
Unknown unknown Camptothecin + NU6027 breast cancer not applicable detail...
Unknown unknown Doxorubicin + NU6027 breast cancer not applicable detail...
Unknown unknown Cisplatin + NU6027 breast cancer not applicable detail...
Unknown unknown NU6027 + Rucaparib breast cancer not applicable detail...
Unknown unknown CS-11 breast cancer not applicable detail...
FGFR2 positive Rogaratinib breast cancer predicted - sensitive detail...
Unknown unknown ISTH0047 breast cancer not applicable detail...
Unknown unknown R916562 breast cancer not applicable detail...
KRAS mutant PI-273 breast cancer decreased response detail...
Unknown unknown PI-273 breast cancer not applicable detail...
HRAS mutant PI-273 breast cancer decreased response detail...
BRCA2 N136_L139del BRCA2 N136Ifs*16 BRCA2 V130_N136delinsD Talazoparib breast cancer resistant detail...
MET wild-type Glesatinib breast cancer decreased response detail...
Unknown unknown Lucitanib breast cancer not applicable detail...
Unknown unknown Elenagen + Tamoxifen breast cancer not applicable detail...
FGFR2 amp FGFR2-GAB2 PRN1371 breast cancer sensitive detail...
BRCA1 mutant NMS-P118 breast cancer sensitive detail...
AKT1 P68_C77dup Capivasertib breast cancer sensitive detail...
BRCA2 D244Efs*10 BRCA2 D244Rfs*7 BRCA2 D252Vfs*24 BRCA2 E260Sfs*15 BRCA2 I247_E254del BRCA2 I247Yfs*8 BRCA2 N255Tfs*21 BRCA2 N257Efs*19 BRCA2 R245_D252del BRCA2 T256Kfs*19 Carboplatin + Olaparib breast cancer predicted - resistant detail...
Unknown unknown ICEC0942 breast cancer sensitive detail...
Unknown unknown XL388 breast cancer not applicable detail...
Unknown unknown Triolimus breast cancer not applicable detail...
ERBB2 positive MI130004 breast cancer sensitive detail...
FGFR2 amp Derazantinib breast cancer sensitive detail...
Unknown unknown Vinflunine breast cancer not applicable detail...
Unknown unknown SKLB-23bb breast cancer not applicable detail...
ERBB2 positive SYD985 breast cancer predicted - sensitive detail...
Unknown unknown GA001 breast cancer not applicable detail...
Unknown unknown INCB081776 + unspecified PD-L1 antibody breast cancer not applicable detail...
BRCA1 inact mut APTO-253 breast cancer sensitive detail...
ERBB2 positive ARX-788 breast cancer sensitive detail...
ERBB2 positive Tucatinib + Trastuzumab emtansine breast cancer sensitive detail...
Unknown unknown Imatinib breast cancer no benefit detail...
KIT positive Imatinib + Letrozole breast cancer predicted - sensitive detail...
BRAF G464V KRAS G13D Encorafenib + Trametinib breast cancer sensitive detail...
BRAF G464V KRAS G13D Trametinib + Vemurafenib breast cancer predicted - resistant detail...
BRAF G464V KRAS G13D Dabrafenib breast cancer no benefit detail...
BRAF L514V Dabrafenib breast cancer resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT00378638 Phase II Bevacizumab Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer Unknown status
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Active, not recruiting
NCT00618657 Phase II Nab-paclitaxel + Carboplatin + Trastuzumab Nab-paclitaxel + Carboplatin + Bevacizumab Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Active, not recruiting
NCT00651976 Phase I Letrozole Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery Terminated
NCT00719875 Phase Ib/II Vorinostat HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer Completed
NCT00733408 Phase II Abraxane + Bevacizumab + Erlotinib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Completed
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT00912340 Phase II Everolimus Trastuzumab Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer Completed
NCT00968968 Phase III Trastuzumab Trastuzumab + Lapatinib Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Completed
NCT00978250 Phase II FdCyd + THU A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Active, not recruiting
NCT01008150 Phase II Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Completed
NCT01035099 Phase I Letrozole RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF Recruiting
NCT01037790 Phase II Palbociclib PD 0332991 in Treating Patients With Refractory Solid Tumors Recruiting
NCT01042379 Phase II Trebananib Pertuzumab + Trastuzumab Ganitumab Paclitaxel + Doxorubicin + Cyclophosphamide MK2206 + Trastuzumab Trebananib + Trastuzumab T-DM1 + Pertuzumab I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting
NCT01106898 Phase II Cyclophosphamide + Paclitaxel Trastuzumab Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery Completed
NCT01194869 Phase II Sorafenib + Cisplatin + Paclitaxel Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer Terminated
NCT01216176 Phase Ib/II Anastrozole Saracatinib A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Completed
NCT01262027 Phase II Dovitinib TKI258 for Metastatic Inflammatory Breast Cancer Patients Active, not recruiting
NCT01275677 Phase III Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Docetaxel + Cyclophosphamide Docetaxel + Cyclophosphamide + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT01281150 Phase I Veliparib Paclitaxel Carboplatin Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Active, not recruiting
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed
NCT01300962 Phase I BKM120 + Capecitabine + Lapatinib BKM120 + Capecitabine + Trastuzumab BKM120 + Capecitabine BYL719 + Capecitabine Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01302379 Phase I Metformin Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors Unknown status
NCT01310231 Phase II Metformin A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Completed
NCT01320592 Phase I Palbociclib Paclitaxel PD0332991/Paclitaxel in Advanced Breast Cancer Active, not recruiting
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed
NCT01358877 Phase III Pertuzumab Trastuzumab A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer Active, not recruiting
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01401959 Phase II Eribulin Eribulin + Trastuzumab Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Completed
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Active, not recruiting
NCT01480583 Phase II Trastuzumab GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Completed
NCT01501487 FDA approved Docetaxel + Doxorubicin + Cyclophosphamide Fluorouracil + Epirubicin + Cyclophosphamide Paclitaxel Pegfilgrastim Docetaxel + Cyclophosphamide Doxorubicin + Cyclophosphamide Trastuzumab + Docetaxel + Carboplatin Pertuzumab + Trastuzumab + Docetaxel MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed
NCT01506609 Phase II Veliparib + Temozolomide Carboplatin + Etoposide + Veliparib Paclitaxel + Carboplatin The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer Active, not recruiting
NCT01517802 Phase III Abiraterone A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Active, not recruiting
NCT01525589 Phase II Lurbinectedin A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Completed
NCT01532960 Phase I poly ICLC Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) Terminated
NCT01545648 Phase II Denosumab Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Active, not recruiting
NCT01562873 Ruxolitinib Ruxolitinib in Patients With Breast Cancer Terminated
NCT01570036 Phase II E75 Sargramostim Trastuzumab Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Completed
NCT01576666 Phase Ib/II BKM120 + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01596751 Phase Ib/II Eribulin Pexidartinib Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01597388 Phase I Vistusertib + Fulvestrant AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer Active, not recruiting
NCT01625286 Phase Ib/II Capivasertib + Paclitaxel Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Active, not recruiting
NCT01640665 Phase I Sorafenib + Capecitabine Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Completed
NCT01650506 Phase I Metformin + Erlotinib Study of Erlotinib and Metformin in Triple Negative Breast Cancer Completed
NCT01656538 Phase II Reolysin Paclitaxel A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Completed
NCT01669343 Phase I Letrozole Aromatase Inhibitor Host Factors Study Unknown status
NCT01676753 Phase Ib/II Dinaciclib + Pembrolizumab Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Recruiting
NCT01723774 Phase II Palbociclib Anastrozole Goserelin PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Recruiting
NCT01730833 Phase II Pertuzumab + Trastuzumab + Paclitaxel Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT01750073 Phase II Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer Recruiting
NCT01831089 Phase I Lurbinectedin + Paclitaxel + Bevacizumab Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01837602 Phase I cMet CAR RNA T Cells Targeting Breast Cancer Completed
NCT01847001 Phase II Propranolol Pertuzumab + Trastuzumab + Paclitaxel Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Active, not recruiting
NCT01853306 Phase I Veliparib A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors Completed
NCT01862900 Phase Ib/II MEDI6469 Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Active, not recruiting
NCT01868503 Phase II Lapatinib Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer Terminated
NCT01870505 Phase I BYL719 + Exemestane Letrozole + BYL719 BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer Active, not recruiting
NCT01920061 Phase I PF-05212384 + Dacomitinib PF-05212384 + Cisplatin Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents Recruiting
NCT01934335 Phase I Vandetanib Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Suspended
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01980823 Phase I Atorvastatin + Metformin Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Recruiting
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Recruiting
NCT01990352 Phase II Doxil Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy Active, not recruiting
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Active, not recruiting
NCT02007512 Phase II Enzalutamide Exemestane Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole Palbociclib + Endocrine Therapy for HR + BrCa Active, not recruiting
NCT02041429 Phase Ib/II Ruxolitinib + Paclitaxel Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Active, not recruiting
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02048059 Phase II GRN1005 ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Completed
NCT02051751 Phase I BYL719 + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed
NCT02077933 Phase I BYL719 + Everolimus BYL719 + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Active, not recruiting
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed + Prexasertib LY3023414 + Prexasertib Fluoruracil + Leucovorin + Prexasertib A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer Recruiting
NCT02168777 Phase Ib/II Regorafenib + Refametinib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated
NCT02202746 Phase II Lucitanib A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer Completed
NCT02203513 Phase II Prexasertib Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk Recruiting
NCT02230319 Phase II Paclitaxel Prevention of Paclitaxel Neuropathy With Cryotherapy Unknown status
NCT02260531 Phase II Cabozantinib Trastuzumab Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases Active, not recruiting
NCT02265536 Phase I LY3022855 A Study of LY3022855 In Participants With Breast or Prostate Cancer Completed
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Unknown status
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain Active, not recruiting
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02314156 Phase II Telapristone Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Active, not recruiting
NCT02340221 Phase III Fulvestrant Taselisib SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy Active, not recruiting
NCT02366130 Phase II radium Ra 223 dichloride Denosumab Phase II Trial of Ra-223 Dichloride and Hormonal Treatment Active, not recruiting
NCT02379585 Phase Ib/II Paclitaxel + Doxorubicin + Cyclophosphamide Pertuzumab + Trastuzumab + Docetaxel Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer Terminated
NCT02391480 Phase I ABBV-075 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies Recruiting
NCT02393794 Phase Ib/II Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Recruiting
NCT02432963 Phase I MVAp53 Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02540330 Phase II Fulvestrant PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy Recruiting
NCT02563925 Phase I Tremelimumab Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Active, not recruiting
NCT02564900 Phase I DS-8201a Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02586675 Phase I Goserelin LEE001 + Tamoxifen TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer Active, not recruiting
NCT02595905 Phase I Cisplatin Veliparib Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer Recruiting
NCT02599363 Phase I Paclitaxel + Ribociclib A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer Recruiting
NCT02605486 Phase Ib/II Bicalutamide + Palbociclib Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Recruiting
NCT02623972 Phase II Cyclophosphamide + Doxorubicin + Eribulin A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Recruiting
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Recruiting
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Recruiting
NCT02643303 Phase Ib/II MEDI4736 + poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02646319 Phase II Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting
NCT02650635 Phase I Cyclophosphamide + Pegfilgrastim + VTX-2337 TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer Recruiting
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02721433 FDA approved Denosumab + pamidronate + Zoledronic acid 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) Active, not recruiting
NCT02725541 Phase II trastuzumab emtansine Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer Withdrawn
NCT02734004 Phase Ib/II Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02746328 Phase II enobosarm Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass Completed
NCT02751528 ETBX-021 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer Recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3039478 + LY3023414 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02874430 Phase II Metformin + Doxycycline Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting
NCT02900469 Phase 0 Denosumab Safety Study of Denosumab to Treat Breast Cancer Recruiting
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting
NCT02939274 Phase II Verteporfin An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Recruiting
NCT02980341 Phase Ib/II U3-1402 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer Recruiting
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Available
NCT02999477 Phase I Pembrolizumab nab-paclitaxel A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Recruiting
NCT03006172 Phase I GDC-0077 + Letrozole + Palbociclib GDC-0077 GDC-0077 + Fulvestrant GDC-0077 + Letrozole To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Recruiting
NCT03025035 Phase II Pembrolizumab Pembrolizumab in Advanced BRCA-mutated Breast Cancer Recruiting
NCT03032107 Phase I Pembrolizumab + trastuzumab emtansine A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Recruiting
NCT03032406 Phase II Everolimus + Hydroxychloroquine Everolimus Hydroxychloroquine CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer Recruiting
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03066947 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Completed
NCT03088527 Phase I RAD140 A Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Recruiting
NCT03095352 Phase II Carboplatin + Pembrolizumab A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Recruiting
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Recruiting
NCT03101748 Phase Ib/II Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide 3HT With Taxol for Metastatic Breast Cancer Recruiting
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03154281 Phase I Niraparib + Everolimus Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Recruiting
NCT03179904 Phase II Paclitaxel + Trastuzumab + TVB-2640 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03207529 Phase I BYL719 + Enzalutamide Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer Not yet recruiting
NCT03219476 Phase II Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HERNegative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance Recruiting
NCT03237572 Phase I Pembrolizumab Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) Recruiting
NCT03248492 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting
NCT03272334 Phase Ib/II HER2 BATs + Pembrolizumab Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47) Recruiting
NCT03292536 Phase I Merestinib Merestinib on Bone Metastases in Subjects With Breast Cancer Recruiting
NCT03317405 Phase I Z-endoxifen HCl Z-Endoxifen Hydrochloride in Treating Patients With Stage 0-III Breast Cancer Undergoing Surgery Recruiting
NCT03328026 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03342417 Phase II Nivolumab + Ipilimumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting
NCT03344965 Phase II Olaparib Olaparib In Metastatic Breast Cancer Recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Recruiting
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Recruiting
NCT03396211 Phase I Apatinib + Nivolumab Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Recruiting
NCT03400254 Phase Ib/II Gedatolisib + Hydrochloroquine Hydroxychloroquine A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") (GLACIER) Not yet recruiting
NCT03409458 Phase Ib/II Avelumab + PT-112 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03439735 Phase II Palbociclib Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC Recruiting
NCT03449238 Phase Ib/II Pembrolizumab Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Recruiting
NCT03477396 Phase II Ribociclib Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer Active, not recruiting
NCT03523572 Phase I DS-8201a + Nivolumab Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT03568422 CFI-402257 Paclitaxel CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03628066 Letrozole Palbociclib Goserelin Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer Recruiting
NCT03641755 Phase Ib/II Olaparib + Sapacitabine A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer Recruiting
NCT03661424 Phase I HER2 BATs BATs in Patients With Breast Cancer and Leptomeningeal Metastases Not yet recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03691493 Phase II Letrozole Anastrozole Fulvestrant Exemestane Palbociclib Tamoxifen Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) Not yet recruiting
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting
NCT03734029 Phase III DS-8201a nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Recruiting
NCT03742245 Phase I Olaparib + Vorinostat Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer Not yet recruiting
NCT03781063 Phase II Lasofoxifene Fulvestrant Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2? Breast Cancer With an ESR1 Mutation Not yet recruiting
NCT03789097 Phase Ib/II Pembrolizumab Vaccination With Flt3L, Radiation, and Poly-ICLC Not yet recruiting
NCT03796273 Phase I Ketoconazole Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Not yet recruiting
NCT03800836 Atezolizumab Paclitaxel nab-paclitaxel Ipatasertib A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Recruiting
NCT03801369 Olaparib Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03804944 CDX-301 Converting HR+ Breast Cancer Into an Individualized Vaccine Not yet recruiting